Iterum Therapeutics plc (ITRM) |
|
1.21 0.02 (1.68%)
|
01-27 15:59 |
|
Open: |
1.17 |
Pre. Close: |
1.19 |
|
High:
|
1.22 |
Low:
|
1.15 |
|
Volume:
|
47,043 |
Market Cap:
|
15(M) |
|
|
|
Technical analysis |
as of: 2023-01-27 4:45:37 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 1.51 One year: 1.77 |
| Support: |
Support1: 0.86 Support2: 0.6 |
| Resistance: |
Resistance1: 1.29 Resistance2: 1.51 |
| Pivot: |
1.15 |
| Moving Average: |
MA(5): 1.19 MA(20): 1.09
MA(100): 1.46  MA(250): 3.08 |
| MACD: |
MACD(12,26): 0 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 76.5 %D(3): 75.9 |
| RSI: |
RSI(14): 57.8 |
| 52-week: |
High: 7.05 Low: 0.19 |
| Average Vol(K): |
3-Month: 372 (K) 10-Days: 70 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ ITRM ] has closed below upper band by 36.3%. Bollinger Bands are 32.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.22 - 1.23 |
1.23 - 1.23 |
|
Low:
|
1.14 - 1.14 |
1.14 - 1.15 |
|
Close:
|
1.2 - 1.21 |
1.21 - 1.22 |
|
Company Description |
|
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland. |
Headline News |
Wed, 11 Jan 2023
Do Traders Think Iterum Therapeutics PLC (ITRM) Can Keep Climbing Wednesday? - InvestorsObserver
Wed, 11 Jan 2023
Lipella, Inotiv top healthcare gainers; Tonix, Prenetics among losers - Seeking Alpha
Thu, 15 Dec 2022
Iterum Therapeutics PLC (ITRM) Stock Increases 15.38% This Week; Should You Buy? - InvestorsObserver
Thu, 15 Dec 2022
Iterum Therapeutics rises 21% on U.S. patent covering oral sulopenem - Seeking Alpha
Wed, 16 Nov 2022
Wings welcome ITRM as official IT partner and back-of-shirt sponsor - Welling United FC
Thu, 20 Oct 2022
Iterum Announces First Patient Dosed in REASSURE, a Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections - Yahoo Finance
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
12 (M) |
| Shares Float |
12 (M) |
|
% Held by Insiders
|
0.7 (%) |
|
% Held by Institutions
|
2.8 (%) |
|
Shares Short
|
140 (K) |
|
Shares Short P.Month
|
217 (K) |
Stock Financials |
|
EPS
|
0.12 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
2.66 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-21.6 |
|
Return on Equity (ttm)
|
-102.5 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-2.14 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-17 (M) |
|
Levered Free Cash Flow
|
-15 (M) |
Stock Valuations |
|
PE Ratio
|
9.3 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.45 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-0.89 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
